Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.37 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.36 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.36 |
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.36 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13855054 | 0.89 | SMN1; SMN2 (0.43) | SMN1; SMN2ALDH1A1MAPK1NPC1RAB9A | |
| SCHEMBL13855053 | 0.77 | F7 (0.53) | SMN1; SMN2ALDH1A1MAPK1LMNAMAPT | |
| SCHEMBL13855070 | 0.77 | PPID (0.46) | SMN1; SMN2ALDH1A1NPC1RAB9ALMNA | |
| SCHEMBL13855058 | 0.76 | F2 (0.54) | SMN1; SMN2ALDH1A1MAPK1NPC1RAB9A | |
| SCHEMBL13855069 | 0.75 | HDAC1 (0.44) | ALDH1A1MAPKAPK2 | |
| SCHEMBL14861066 | 0.73 | RAB9A (0.43) | SMN1; SMN2ALDH1A1MAPK1NPC1RAB9A | |
| SCHEMBL13855387 | 0.72 | ALDH1A1 (0.42) | SMN1; SMN2ALDH1A1MAPK1NPC1RAB9A | |
| SCHEMBL20836739 | 0.72 | HDAC1 (0.50) | ALDH1A1NPC1RAB9AMAPTCYP17A1 | |
| SCHEMBL16137952 | 0.72 | HDAC1 (0.50) | ALDH1A1NPC1RAB9AMAPTCYP17A1 | |
| SCHEMBL13153892 | 0.72 | HDAC1 (0.50) | ALDH1A1NPC1RAB9AMAPTCYP17A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090130085-A1 | Amidino-Compounds for Stabilizing Factor VII Polypeptide Formulations | NOVO NORDISH HEALTHCARE AG (CH) | 2009-05-21 | — | — | US | disclosed |
| US-20090130085-A1 | Amidino-Compounds for Stabilizing Factor VII Polypeptide Formulations | NOVO NORDISH HEALTHCARE AG (CH) | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090130085-A1 | Amidino-Compounds for Stabilizing Factor VII Polypeptide Formulations | F7, F5, F8 | SMN1; SMN2 657/4885ALDH1A1 4449/4885MAPK1 4052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.